🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase II

Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs
2,640

Quick answer

Oncology Phase II programs: NovaPharmaNews indexes 2,640 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 39 of 55

  1. Pembrolizumab

    United Therapeutics Europe Ltd

    Castration-resistant Prostate Cancer

    phase 2 small molecule active

    1 trial

  2. Pembrolizumab

    United Therapeutics Europe Ltd

    Metastatic Small Intestinal Adenocarcinoma

    phase 2 mab active

    1 trial

  3. Pembrolizumab

    Incyte

    Lung Cancer

    phase 2 small molecule completed

    2 trials

  4. Pembrolizumab

    United Therapeutics Europe Ltd

    Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  5. Pembrolizumab

    United Therapeutics Europe Ltd

    Triple Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  6. Pembrolizumab

    Syndax Pharmaceuticals

    Metastatic Uveal Melanoma

    phase 2 small molecule completed

    1 trial

  7. Pembrolizumab

    ALX ONCOLOGY HOLDINGS INC

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  8. Pembrolizumab

    TG THERAPEUTICS, INC.

    Hodgkin's Lymphoma

    phase 2 mab terminated

    1 trial

  9. Pembrolizumab

    Karyopharm Therapeutics Inc

    Advanced Urothelial Carcinoma

    phase 2 mab terminated

    1 trial

  10. Pembrolizumab

    IO Biotech

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  11. Pembrolizumab

    Genmab A/S

    Advanced Endometrial Cancer

    phase 2 mab terminated

    1 trial

  12. Pembrolizumab

    Bicara Therapeutics

    Head and Neck Squamous Cell Carcinoma

    phase 2 mab active

    1 trial

  13. Pembrolizumab

    Inhibrx Biosciences

    Triple Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  14. Pembrolizumab

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 2 small molecule active

    1 trial

  15. Pembrolizumab (+) Berahyaluronidase alfa

    Merck KGaA, Darmstadt, Germany

    Squamous Cell Carcinoma

    phase 2 mab active

    1 trial

  16. Pembrolizumab (200mg IV for 30 minutes

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 2 small molecule active

    1 trial

  17. Pembrolizumab (KEYTRUDA®) and PDS0101

    PDS Biotechnology Corp

    Metastatic Head and Neck Cancer

    phase 2 other completed

    1 trial

  18. Pembrolizumab 200 mg

    Merck KGaA, Darmstadt, Germany

    Non-small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  19. Pembrolizumab 200 mg

    Merck KGaA, Darmstadt, Germany

    Metastatic Castration-Resistant Prostate Cancer

    phase 2 mab active

    1 trial

  20. Pembrolizumab 200 mg IV infusion

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Stage IIIB(N2) Non-small Cell Lung Cancer

    phase 2 mab active

    1 trial

  21. Pembrolizumab Injection

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  22. Pembrolizumab plus denosumab

    Zealand Pharma A/S

    Renal Cell Carcinoma, Clear Cell

    phase 2 small molecule active

    1 trial

  23. Pembrolizumab/Vibostolimab coformulation

    Merck KGaA, Darmstadt, Germany

    Metastatic Non Small Cell Lung Cancer

    phase 2 mab completed

    1 trial

  24. Pemebit

    Hospital Authority, Hong Kong

    Adenocarcinoma

    phase 2 small molecule completed

    1 trial

  25. Pemetrexe

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Central Nervous System Tumors

    phase 2 small molecule active

    1 trial

  26. Pemetrexed

    Mereo BioPharma Group plc

    Nonsquamous Nonsmall Cell Neoplasm of Lung

    phase 2 small molecule completed

    1 trial

  27. Pemetrexed

    The First People's Hospital of Lianyungang

    Colorectal Neoplasms

    phase 2 small molecule active

    1 trial

  28. Pemetrexed

    Samsung Bioepis NL B.V.

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  29. Pemetrexed EVER Pharma 25 mg/ml concentrate for solution for infusion, Carboplatino Aurovitas 10 mg/ml concentrado para solución para perfusión EFG, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Pemetrexed Glenmark 10 mg/ml solución para perfusión, Carboplatino Hikma 10 mg/ml soluzione per infusione, OMTX705, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Carboplatino Teva 10 mg/ml Concentrado para solución para perfusión, Carboplatino Accord 10 mg/ml concentrado para

    Lacuna Pharma Pty Ltd

    Advanced/Metastatic Non-squamous Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  30. Pemetrexed Ever Pharma 25 mg/ml concentrato per soluzione per infusione, JNJ-61186372

    Fondazione Telethon ETS

    Non-small cell lung cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  31. Pemetrexed Fresenius Kabi 500 mg powder for concentrate for solution for infusion, Paclitaxel AqVida 6 mg/ml concentrate for solution for infusion, REGN7075, Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., LIBTAYO 350 mg concentrate for solution for infusion., Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Lacuna Pharma Pty Ltd

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  32. Pemetrexed Pfizer 25 mg/ml concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion, Carboplatin-Teva 10 mg/ml Concentrate for Solution for Infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Pemetrexed Pfizer 100 mg powder for concentrate for solution for infusion, JEMPERLI 500 mg concentrate for solution for infusion, Pemetrexed Pfizer 25 mg/ml concentrate for solution for infusion., Pemetrexed Pfizer 25 mg/ml concentrate for solution for infusion.

    GlaxoSmithKline

    Lung Cancer, Non-Small Cell

    phase 2 small molecule active

    1 trial

  33. Pemetrexed Ribosepharm 25 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatine Hikma 450 mg/45 ml Infusionslösung, Pemetrexed Hexal 25 mg/ml infuusiokonsentraatti, liuosta varten, Cisplatine 1 mg/ml PCH, concentraat voor oplossing voor infusie, Pemetrexed STADA 25 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung, DOMVANALIMAB, Pemetrexed NeoCorp 25 mg/ml Konzentrat zur Herstellung einer Infusionslös

    Gilead Sciences Pty Limited

    Advanced Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  34. Pemetrexed and Reolysin (and safety run-in)

    ONCOLYTICS BIOTECH INC

    Non Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  35. Pentasa Sachet 2 g depotgranulat, Pentasa PLACEBO Sachet 2g in the granule formulation specifically designed to resemble the active drug product

    The George Institute

    Lynch syndrome, which is increasing the risk of developing colorectal cancer

    phase 2 small molecule active

    1 trial

  36. Perjeta 420 mg concentrate for solution for infusion, Herceptin 150 mg powder for concentrate for solution for infusion, Avastin 25 mg/ml concentrate for solution for infusion., Tecentriq 840 mg concentrate for solution for infusion

    The George Institute

    Newly diagnosed, non-metastatic early-stage triple-negative or HER2+ breast cancer

    phase 2 small molecule active

    1 trial

  37. Pevonedistat

    Takeda

    Acute Myeloid Leukemia (AML)

    phase 2 small molecule completed

    2 trials

  38. Pexastimogene Devacirepvec (Pexa-Vec)

    Regeneron UK Limited

    Renal Cell Carcinoma

    phase 2 mab active

    1 trial

  39. Phase 1/2 Study of PYX-201 in Combination with Pembrolizumab in Advanced Solid Tumors

    Pyxis Oncology

    Advanced Solid Tumors

    phase 2 other active

    1 trial

  40. Phase 1/2A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients with Advanced Solid Tumors

    Lacuna Pharma Pty Ltd

    advanced solid tumors

    phase 2 other active

    1 trial

  41. Phase 1b/2 trial of 5-fluorouracil, leucovorin, irinotecan in combination with temozolomide (FLIRT) and bevacizumab for the first-line treatment of patients with MGMT silenced, microsatellite stable metastatic colorectal cancer.

    Fondazione Telethon ETS

    metastatic colorectal cancer

    phase 2 other active

    1 trial

  42. Phase 1b/2, Multicenter, Open-label, Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3-DXd monotherapy and combinations in Patients with inoperable advanced breast cancer (ABC) after progression on T-DXd- (ICARUS BREAST 2)

    The George Institute

    Patients with HER2-positive (HER2-pos) (cohort 1) or HER2-low defined as a score 1+ on immunohistochemistry [IHC] or as an IHC score 2+ and negative results on in situ hybridization (ISH) (cohort 2) ABC, and any hormone receptor (HR) status, who have progressed on trastuzumab deruxtecan (T-DXd). In addition to previous T-DXd, patients with HER2-pos tumors must have received prior treatment with trastuzumab (+/- pertuzumab) and taxanes and may have received T-DM1. Patients with HER2-low tumors must have received prior treatment with taxanes. Patients with HR-positive (HR+) and HER2-low tumor must have received prior treatment with endocrine therapy and CDK4/6 inhibitors.

    phase 2 other active

    1 trial

  43. Phase 1b: APG-115+pembrolizumab

    Ascentage Pharma Group

    Unresectable or Metastatic Melanoma or Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  44. Phase 2, Open label Study of DS-1062a, an Anti-TROP-2-Antibody-Drug Conjugate (ADC), in patients with advanced and/or unresectable Non-Small Cell Lung Cancer (NSCLC), with biomarker analysis to characterize response to therapy_ ICARUS LUNG 01

    The George Institute

    Adult patients with metastatic and/or unresectable Non-Small Cell Lung Cancer (NSCLC) who progressed on at least one line and not more than three lines of prior therapy for metastatic/unresectable NSCLC

    phase 2 other active

    1 trial

  45. Phase 2, Open label Study of Patritumab Deruxtecan (U3-1402), an Anti-HER3-Antibody Drug Conjugate (ADC), in patients with Advanced Breast Cancer, with biomarker analyses to characterize response to therapy

    The George Institute

    Patients with hormone-receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-negative) advanced breast cancer (ABC) who have already received standard therapy for HR+/HER2-negative ABC, including only one line of chemotherapy for advanced/metastatic disease.

    phase 2 other active

    1 trial

  46. Phase I Study of PM534 Administered to Patients with Advanced Solid Tumors

    Lacuna Pharma Pty Ltd

    Advanced Solid Tumors

    phase 2 other active

    1 trial

  47. Phase I Study of PM534 to Patients with Advanced Solid Tumors

    Lacuna Pharma Pty Ltd

    Advances solid tumors

    phase 2 other active

    1 trial

  48. Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM14 Administered Intravenously to Patients with Advanced Solid Tumors

    Lacuna Pharma Pty Ltd

    Advanced Solid Tumors

    phase 2 other active

    1 trial

Frequently asked questions

How many oncology Phase II programs exist?

2,640 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.